Stockscreener 앱 받기
8.31
1.07%
-0.09
시간 외 거래:
8.31
전일 마감가:
$8.40
열려 있는:
$8.39
하루 거래량:
1.15M
Relative Volume:
0.62
시가총액:
$860.23M
수익:
-
순이익/손실:
$-135.21M
주가수익비율:
-5.8067
EPS:
-1.4311
순현금흐름:
$-114.35M
1주 성능:
+3.88%
1개월 성능:
+1.96%
6개월 성능:
-8.88%
1년 성능:
-11.69%
1일 변동 폭
$8.085
$8.49
1주일 범위
$7.455
$8.50
52주 변동 폭
$7.23
$14.93
Oric Pharmaceuticals Inc Stock (ORIC) Company Profile
명칭
Oric Pharmaceuticals Inc
전화
(650) 388-5600
주소
240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Compare ORIC vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ORIC
Oric Pharmaceuticals Inc
|
8.31 | 869.55M | 0 | -135.21M | -114.35M | -1.4311 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Oric Pharmaceuticals Inc Stock (ORIC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | Piper Sandler | Overweight |
| 2025-11-20 | 개시 | Evercore ISI | Outperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2024-10-31 | 개시 | Wells Fargo | Overweight |
| 2024-09-06 | 개시 | Stifel | Buy |
| 2024-02-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-22 | 개시 | Wedbush | Outperform |
| 2023-03-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-03-21 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-16 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-07-18 | 재개 | Oppenheimer | Perform |
| 2022-04-04 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-03-25 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-03-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-07-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-13 | 개시 | Robert W. Baird | Outperform |
| 2020-08-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-05-19 | 개시 | Citigroup | Neutral |
| 2020-05-19 | 개시 | Guggenheim | Buy |
| 2020-05-19 | 개시 | JP Morgan | Overweight |
| 2020-05-19 | 개시 | Jefferies | Buy |
모두보기
Oric Pharmaceuticals Inc 주식(ORIC)의 최신 뉴스
Bandwidth, Traws Pharma And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
ORIC gains as Stifel resumes at buy on upcoming Pfizer readout - MSN
ORIC Pharmaceuticals (ORIC) Gains on Buy Rating from Stifel Amid Positive Trial Outlook - GuruFocus
ORIC gains as Stifel resumes at Buy on upcoming Pfizer readout - Seeking Alpha
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Oric Pharmaceuticals (ORIC) and Pfizer (PFE) - The Globe and Mail
Buy Rating and $14 Target Set for Oric Pharmaceuticals (ORIC) - GuruFocus
Stifel initiates Oric Pharmaceuticals stock with buy rating By Investing.com - Investing.com Nigeria
Stifel initiates Oric Pharmaceuticals stock with buy rating - Investing.com
ORIC Pharmaceuticals Positions for Growth in Expanding Oncology Market - Streetwise Reports
ORIC: Phase III prostate cancer trial set to start, with strong safety and efficacy data and robust cash runway - TradingView
Oric Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
ORIC Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Oric Pharmaceuticals stock edges up 1.60% as company executives join Goldman Sachs healthcare event, oricpharma - Traders Union
H.C. Wainwright reiterates Buy on ORIC Pharmaceuticals stock By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Clinical-Stage Biopharma Co. Issues New Inducement Stock Options for Growth - Streetwise Reports
ORIC Falls After Hours On Safety Concerns Around Prostate Cancer Candidate At Higher Doses - Stocktwits
Oric Pharmaceuticals stock falls 6.48% amid bearish momentum as Oric Pharmaceuticals honors cancer survivors - Traders Union
Oric Pharmaceuticals (ORIC) Sheds 6.5% as Shares Test Key Support LevelsUp Down Volume - newsline.com
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Moomoo
ORIC Pharmaceuticals grants inducement equity to new hires - scanx.trade
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Two new ORIC hires receive stock options and RSU awards - Stock Titan
Goldman Sachs Maintains Oric Pharmaceuticals(ORIC.US) With Buy Rating, Announces Target Price $15 - Moomoo
Oric Pharmaceuticals stock under sustained selling pressure, trades near new support zone - Traders Union
This ORIC Pharmaceuticals Insider Increased Their Holding In The Last Year - Moomoo
ORIC Pharmaceuticals (ORIC) Stock Analysis Report | Financials & Insights - Benzinga España
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Oncology company ORIC plans June talks at Jefferies, Goldman events - Stock Titan
What's behind the drop in Oric Pharmaceuticals stock today? - MSN
ORIC Stock Chart | ORIC PHARMACEUTICALS INC (NASDAQ:ORIC) - ChartMill
Trading Systems Reacting to (ORIC) Volatility - Stock Traders Daily
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.ORIC - ACCESS Newswire
ORIC Q1 2026 Earnings: Narrower-Than-Expected Loss, Pipeline Progress Keeps Focus on Key MilestonesEPS Guidance Update - newsline.com
ORIC Stock Heads Into Weekend as Cancer-Trial Deadline Approaches - Bez Kabli
Cantor Fitzgerald reiterates Overweight on ORIC Pharmaceuticals stock By Investing.com - Investing.com Canada
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - PR Newswire
User - The Chronicle-Journal
ORIC Pharmaceuticals stock nosedives 25% after hours: What is going on? - MSN
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth - Yahoo Finance
Viking Global (ORIC) reports 8.26M shares; 2.44M warrant rights disclosed - Stock Titan
Venrock affiliates report 4.2% stake in ORIC (NASDAQ: ORIC) update - Stock Titan
Point72-affiliated filers report 0% ownership in ORIC (ORIC) amendment - Stock Titan
T. Rowe Price holds 5.4% of ORIC (ORIC) — 5.39M shares reported - Stock Titan
Goldman Sachs upgrades ORIC Pharmaceuticals stock rating to buy By Investing.com - Investing.com Canada
Goldman Sachs Upgrades Oric Pharmaceuticals (ORIC) with $15 Pric - GuruFocus
Oric Pharmaceuticals Inc Enozertinib (ORIC-114) Program Update Call Transcript - GuruFocus
Oric Pharmaceuticals faces securities fraud probe after prostate cancer drug update causes 41% stock drop - Pluang
Beyond Meat posts downbeat Q4 results, joins RH, ORIC Pharmaceuticals and other big stocks moving lower in Wednesday's pre-market session - MSN
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC - FinancialContent
Pfizer (NYSE: PFE) discloses 3.3% holding in ORIC Pharmaceuticals - Stock Titan
Oric Pharmaceuticals Inc (ORIC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Oric Pharmaceuticals Inc 주식 (ORIC) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Piscitelli Dominic | Chief Financial Officer |
Feb 24 '26 |
Sale |
13.51 |
52,000 |
702,686 |
68,148 |
1.27%
1.43%
자본화:
|
볼륨(24시간):